Rankings
Pricing
Log In
Free Trial
US-listed companies
Vivid Seats Inc.
Vivid Seats Inc.
SEAT
Market cap
$807.24M
P/E ratio
Add to your list
Add to your list
Back to summarized table
B
M
K
USD
Annual
Quarterly
Download CSV
Income statement
Balance sheet
Cash flow
Dec 31,
2021
Dec 31,
2022
Net income (loss)
-19
71
Depreciation and amortization
2
8
Amortization of Debt Issuance Costs
4
1
Loss on asset disposals
-
-0
Equity-based compensation expense
6
19
Loss on extinguishment of debt
-36
4
Paid-in-Kind Interest
25
-
Change in fair value of warrants
1
-8
Amortization of right-of-use assets
-
-2
Change in fair value of contingent consideration
-
2
Accounts receivable
1
0
Inventory
4
1
Prepaid expenses and other current assets
7
-
Accounts payable
128
-31
Accrued expenses and other current liabilities
14
-94
Deferred revenue
19
7
Other assets and liabilities
0
4
Net cash provided by (used in) operating activities
220
14
Cash acquired (paid) in acquisition
-0
0
Purchases of property and equipment
1
4
Purchases of personal seat licenses
0
0
Investments in developed technology
8
12
Net cash used in investing activities
-9
-15
Distributions to non-controlling interests
-
5
Repurchase of Common Stock as Treasury Stock
-
32
Cash paid for milestone payments
-
1
Proceeds from PIPE Financing
475
-
Proceeds from the Merger Transaction
278
-
Redemption of Redeemable Senior Preferred Units
-236
-
Payments of May 2020 First Lien Loan
304
-
Prepayment penalty on extinguishment of debt
28
-
Payment of reverse recapitalization costs
20
-
Dividends paid to Class A Common Stock Shareholders
18
-
Payments of deferred financing costs and other debt-related costs
-
5
Net cash (used in) provided by financing activities
-6
-236
Net increase (decrease) in cash and cash equivalents and restricted cash
204
-238
Cash paid for interest
29
15
Property and equipment acquired through tenant improvement allowance
-
-6
Right-of-use assets obtained in exchange for lease obligations
-
3
Equity-based compensation expense related to capitalized development costs
-
0